<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308553</url>
  </required_header>
  <id_info>
    <org_study_id>Nipawilma_2013</org_study_id>
    <nct_id>NCT02308553</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma</brief_title>
  <acronym>NIPAWILMA</acronym>
  <official_title>Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Dirk Schadendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcedis GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed&#xD;
      to characterize the safety and estimate the efficacy of nintedanib when combined with&#xD;
      paclitaxel chemotherapy compared with paclitaxel chemotherapy alone in patients with BRAF&#xD;
      wild type metastatic melanoma not previously treated with taxanes or kinase inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase I: Run-In-Phase Based on acceptable safety data for nintedanib monotherapy, a&#xD;
      rapid dose finding will be conducted in a classical 3+3 design. Predefined dose levels are&#xD;
      150 mg (dose level 1) and 200 mg (dose level 2) nintedanib, twice daily, with weekly&#xD;
      paclitaxel 90 mg/m2.&#xD;
&#xD;
      Study Phase II Patients with advanced (unresectable Stage III or IV) BRaf V600 wild type&#xD;
      melanoma (n=120) will be randomized (1:1) to receive either Nintedanib (150 or 200 mg BID&#xD;
      depending on results of phase I) in combination with paclitaxel or Placebo in combination&#xD;
      with paclitaxel.&#xD;
&#xD;
      Total study duration per patient: approximately 12 months of therapy + Follow up until end of&#xD;
      study&#xD;
&#xD;
      All patients enrolled in either phase I or phase II will be treated according to the&#xD;
      following treatment plan:&#xD;
&#xD;
      Week 1 - 24:&#xD;
&#xD;
      Chemotherapy with paclitaxel combined with nintedanib/placebo&#xD;
&#xD;
      Week 25 - 48:&#xD;
&#xD;
      Extended monotherapy with nintedanib/placebo&#xD;
&#xD;
      Week 52 (or approximately 4 weeks after last treatment dose):&#xD;
&#xD;
      End of Treatment visit&#xD;
&#xD;
      Follow up:&#xD;
&#xD;
      After end of treatment the survival, disease status and further therapies of each patient&#xD;
      will be assessed every 3 months until death, progression of disease or end of study whichever&#xD;
      occurs first&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2015</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">October 17, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Time from administration of first study drug to the date of first documented progression or death due to any cause, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Time from the date of first administration of study drug to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity (graded according to CTCAE, Version 4.0)</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Reporting of adverse events from the date of first administration of study drug until 30 days after last administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC QLQ-C30)</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Quality of life during therapy (i.e. until end of treatment visit)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cutaneous Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Nintedanib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nintedanib-Placebo + Paclitaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib (150 mg or 200 mg BID)</description>
    <arm_group_label>Nintedanib + Paclitaxel</arm_group_label>
    <other_name>Vargatef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib-Placebo</intervention_name>
    <description>Placebo (150 mg or 200 mg BID)</description>
    <arm_group_label>Nintedanib-Placebo + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)</description>
    <arm_group_label>Nintedanib + Paclitaxel</arm_group_label>
    <arm_group_label>Nintedanib-Placebo + Paclitaxel</arm_group_label>
    <other_name>Taxomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed, (surgically incurable or unresectable) stage III or IV, BRAF&#xD;
             V600 wildtype metastatic cutaneous malignant melanoma.&#xD;
&#xD;
          2. Written informed consent&#xD;
&#xD;
          3. A minimum of 1 measurable lesion according to RECIST v1.1 criteria.&#xD;
&#xD;
          4. ECOG of 0-1.&#xD;
&#xD;
          5. Adequate hematologic, renal and liver function within 14 days prior to initiation of&#xD;
             dosing:&#xD;
&#xD;
               -  Hematologic:&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥1.5 x 109/L&#xD;
&#xD;
                    -  Hemoglobin ≥ 9 g/dL (5.6 mmol/L; Subjects may not have had a transfusion&#xD;
                       within 7 days of screening assessment)&#xD;
&#xD;
                    -  Platelets: ≥ 100 x 109/L&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Total bilirubin: ≤ 1.0 x ULN&#xD;
&#xD;
                    -  AST and ALT: ≤ 1.5 x ULN (In the case of liver metastases: 2.5 x ULN)&#xD;
&#xD;
               -  Renal o Serum creatinine: ≤ 1.5 mg/dL (133 µmol/L) or, if greater than 1.5 mg/dL:&#xD;
                  Calculated creatinine clearance: ≥ 50 mL/min&#xD;
&#xD;
          6. effective method of contraception for at least 3 months after completion of&#xD;
             nintedanib/placebo monotherapy as directed by their physician.&#xD;
&#xD;
          7. Men should use an effective method of contraception during treatment and for at least&#xD;
             6 months after completion of paclitaxel treatment and for at least 3 months after&#xD;
             completion of nintedanib/placebo monotherapy as directed by their physician.&#xD;
&#xD;
          8. Patients must have recovered from all prior treatment-related toxicities to NCI CTCAE&#xD;
             (v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk such as&#xD;
             alopecia.&#xD;
&#xD;
          9. Male or female, aged 18 years or older&#xD;
&#xD;
         10. Life expectancy at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior systemic therapy with taxanes or kinase inhibitors. Any prior therapy for&#xD;
             metastatic disease must have been discontinued at least 4 weeks prior to initiation of&#xD;
             dosing.&#xD;
&#xD;
          2. Major surgery or radiation therapy within 4 weeks of starting the study treatment&#xD;
             (minor surgical procedures such as biopsies are allowed, however patients must have&#xD;
             recovered).&#xD;
&#xD;
          3. Known inherited predisposition to bleeding or thrombosis and therapeutic&#xD;
             anticoagulation (except low-dose heparin and/or heparin flush as needed for&#xD;
             maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for&#xD;
             low-dose therapy with acetylsalicylic acid &lt; 325mg per day)&#xD;
&#xD;
             Patients with the following coagulation parameters will be excluded:&#xD;
&#xD;
               -  International normalised ratio (INR) &gt; 2&#xD;
&#xD;
               -  Prothrombin time (PT) and partial thromboplastin time (PTT): &gt; 50% of deviation&#xD;
                  of institutional ULN&#xD;
&#xD;
          4. History of clinically significant haemorrhagic or thromboembolic event in the past 6&#xD;
             months&#xD;
&#xD;
          5. NCI CTCAE (V4.0) grade 3 hemorrhage within 4 weeks of starting the study treatment.&#xD;
&#xD;
          6. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to randomization.&#xD;
&#xD;
          7. Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          8. Known CNS disease:&#xD;
&#xD;
               -  Previous Grade 2 or higher sensory neuropathy.&#xD;
&#xD;
               -  History of or known spinal cord compression, or carcinomatous meningitis, or&#xD;
                  evidence of active brain metastases (e.g. stable for &lt;4 weeks, no adequate&#xD;
                  previous treatment with radiotherapy, symptomatic, requiring treatment with&#xD;
                  anti-convulsants; dexamethasone therapy will be allowed if administered as stable&#xD;
                  dose for at least one month before randomization) or leptomeningeal disease on&#xD;
                  screening CT or MRI scan.&#xD;
&#xD;
          9. Any of the following within the 6 months prior to enrolment: myocardial infarction,&#xD;
             severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic&#xD;
             congestive heart failure, cerebrovascular accident or transient ischemic attack, or&#xD;
             pulmonary embolism.&#xD;
&#xD;
         10. New York Heart Association (NYHA) Grade II or greater congestive heart failure.&#xD;
&#xD;
         11. Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.0 grade ≥ 2.&#xD;
&#xD;
         12. Inadequately controlled hypertension (defined as systolic blood pressure &gt; 150 and/or&#xD;
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications).&#xD;
&#xD;
         13. Symptomatic peripheral vascular disease.&#xD;
&#xD;
         14. Proteinuria at screening as demonstrated by urine dipstick for proteinuria ≥ 2+&#xD;
             (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline&#xD;
             should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24&#xD;
             hours to be eligible).&#xD;
&#xD;
         15. Known hypersensitivity reaction to any of the components of study treatment (e.g.&#xD;
             contrast media) or other severe acute or chronic medical or psychiatric condition or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration, or may interfere with the interpretation of study&#xD;
             results, and in the judgment of the investigator would make the subject inappropriate&#xD;
             for entry into this study.&#xD;
&#xD;
         16. Previous cancer (unless a RFS interval of at least 5 years) with the exception of&#xD;
             surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma&#xD;
             of the skin.&#xD;
&#xD;
         17. Known clinically uncontrolled infectious disease including HIV positivity or&#xD;
             AIDS-related illness and active or chronic hepatitis C and/or B infection.&#xD;
&#xD;
         18. Pregnancy (absence to be confirmed by ß-hCG test) or lactation period.&#xD;
&#xD;
         19. Psychological, familial, sociological or geographical factors potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule&#xD;
&#xD;
         20. Active alcohol or drug abuse&#xD;
&#xD;
         21. Treatment with other investigational drugs or treatments in another clinical trial&#xD;
             within the past four weeks before start of therapy or concomitantly with this trial.&#xD;
&#xD;
         22. Legal incapacity or limited legal capacity&#xD;
&#xD;
         23. Significant weight loss (&gt; 10% of body weight) within past 6 months prior to inclusion&#xD;
             into the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbeklinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Centre for Tumour Diseases (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital München</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Hornheide</name>
      <address>
        <city>Münster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Dirk Schadendorf</investigator_full_name>
    <investigator_title>Prof. Dr. med. Dirk Schadendorf</investigator_title>
  </responsible_party>
  <keyword>BRAF V600 wildtype</keyword>
  <keyword>cutaneous malignant melanoma</keyword>
  <keyword>nintedanib</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

